A., Kadry, B., Oakes, D., Macario, A., Schmiesing, C. The Heart of the Matter: Increasing Quality and Charge Capture from Intraoperative Transesophageal Echocardiography.The risk of epidural hematoma associated with neuraxial techniques in parturients at a platelet count less than 70,000 mm remains poorly defined due to limited observations. The upper bound of the 95% CI for the risk of epidural hematoma for a platelet count of 0 to 49,000 mm is 11%, for 50,000 to 69,000 mm is 3%, and for 70,000 to 100,000 mm is 0.2%.The number of thrombocytopenic parturients in the literature who received neuraxial techniques without complication has been significantly increased. No cases of epidural hematoma requiring surgical decompression were observed. A systematic review was performed, and risk estimates were combined with those from the existing literature.A total of 573 parturients with a platelet count less than 100,000 mm who received a neuraxial technique across 14 institutions were identified in the Multicenter Perioperative Outcomes Group database, and a total of 1,524 parturients were identified after combining the data from the systematic review. Patients were stratified by platelet count, and those requiring surgical decompression were identified. The authors reviewed a large perioperative database and performed a systematic review to further define the risk of epidural hematoma requiring surgical decompression in this population.The authors performed a retrospective cohort study using the Multicenter Perioperative Outcomes Group database to identify thrombocytopenic parturients who received a neuraxial technique and to estimate the risk of epidural hematoma. There is limited literature to estimate the risk of epidural hematoma in thrombocytopenic parturients. Thrombocytopenia has been considered a relative or even absolute contraindication to neuraxial techniques due to the risk of epidural hematoma. Vice Provost for Undergraduate Education.Office of Vice President for Business Affairs and Chief Financial Officer.Office of VP for University Human Resources.Stanford Woods Institute for the Environment.Stanford Institute for Economic Policy Research (SIEPR).Institute for Stem Cell Biology and Regenerative Medicine.Institute for Human-Centered Artificial Intelligence (HAI).Institute for Computational and Mathematical Engineering (ICME).Freeman Spogli Institute for International Studies.Stanford Doerr School of Sustainability.McDiarmid, M.G.Martin et al The Effect of Immunosuppression on Posttransplant Lymphoproliferative Disease in Pediatric Liver Transplant Patients Transplantation Vol.70,94-99, No.1, July 15, 2000. J Pediatr Gastroenterol Nutr, Vol.28, No.4, April 1999. McDiarmid et al The Involvement of the Gastrointestinal Tract in Posttransplant Lymphoproliferative Disease in Pediatric Liver Transplantation. North American Society of Pediatric Gastroenterology Hepatology & Nutrition.Orange County Medical Association’s Physicians of Excellence 2012.Maimonides Medical Center, Brooklyn, New York – Pediatric Chief Resident Maimonides Medical Center, Brooklyn, New York – Pediatrics Semmelweis University School of Medicine – Pediatrics Semmelweis University School of Medicine, Budapest, Hungary UCLA Children’s Hospital, Los Angeles, CAĪpathy Memorial Hospital, Budapest, Hungary Pediatric Gastroenterology Hepatology & Nutrition Is on staff at CHOC Hospital in Orange and CHOC Mission Hospital.ġ201 W. Younes conducted his fellowship in pediatric gastroenterology-hepatology and nutrition at UCLA.Ĭrohn’s disease, inflammatory bowl disease, anti-Interleukin 5 therapy for the treatment of eosinophilic esophagitis He received his residency training at Semmelweis University School of Medicine and Maimonides Medical Center in Brooklyn, New York. Younes attended medical school at Semmelweis University School of Medicine in Budapest, Hungary. Younes is board certified in both pediatrics and pediatric gastroenterology by the American Board of Pediatrics. Younes is pursuing further research on the treatment of pediatric liver disease.ĭedicated to clinical excellence, Dr. He is involved with a study evaluating inter acid treatment for inflammatory bowel disease and CHOC’s research on anti-Interleukin 5 therapy for the treatment of eosinophilic esophagitis. He serves as coinvestigator in several multi-center studies evaluating the efficacy and safety of new drug treatments for pediatric patients with Crohn’s disease. Bassam Younes is involved in numerous research projects. Dedicated to treating and researching all gastrointestinal disorders, Dr.
0 Comments
Leave a Reply. |